Pubblicazioni

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

2022 - THE LANCET. HAEMATOLOGY

Dimopoulos, Meletios A; Richardson, Paul G; Bahlis, Nizar J; Grosicki, Sebastian; Cavo, Michele; BeksaÃ§, Meral; LegieÄ, Wojciech; Liberati, Anna M; Goldschmidt, Hartmut; Belch, Andrew; Magen, Hila; Larocca, Alessandra; Laubach, Jacob P; Petrucci, Maria T; Reece, Donna; White, Darrell; Mateos, MarÃa-Victoria; Å piÄka, Ivan; Lazaroiu, Mihaela; Berdeja, JesÃºs; Kaufman, Jonathan L; Jou, Ying-Ming; Ganetsky, Alex; Popa McKiver, Mihaela; Lonial, Sagar; Weisel, Katja; Martelli, Maurizio